Logo

NIH s Chem Genomics Center to Use Invitrogen Tools in Screening Program

Mar 06, 2006

NEW YORK, March 7 (GenomeWeb News) - The National Institutes of Health's ChemicalGenomicsCenter will use Invitrogen's CellSensor cell lines and GeneBLAzer beta-lactamase reporter gene technology to identify compounds that modulate disease-relevant signaling pathways, the company said today.

 

The NCGC will use the assay technology with quantitative high-throughput screening program, Invitrogen said, and all of the screening data from the collaboration will be deposited in PubChem.

 

As these new assays generate compounds of interest, Invitrogen and the NCGC may agree to work together to identify the protein targets they affect through the use of additional Invitrogen technologies such as Stealth RNAi and Protoarray Human Protein Microarrays, Invitrogen said.

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.